FULGENT GENETICS, INC. Finance Lease, Right-of-Use Asset, Amortization
FULGENT GENETICS, INC. (FLGT) reported Finance Lease, Right-of-Use Asset, Amortization of $85.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-07-30
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $85.00K, a 0.00% change year-over-year.
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $85.00K, a 35.61% decline year-over-year.
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $85.00K, a 35.61% decline year-over-year.
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $85.00K, a 36.57% decline year-over-year.
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $386.00K, a 28.39% decline from fiscal 2024.
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $539.00K, a 28.89% decline from fiscal 2023.
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $758.00K, a 10.98% increase from fiscal 2022.
- FULGENT GENETICS, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $683.00K, a 9657.14% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $85.00K 10-Q · filed 2026-07-30 | $169.00K 10-Q · filed 2026-07-30 | $255.00K derived: sum of 3 quarters · filed 2026-07-30 | $340.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $85.00K 10-Q · filed 2026-05-01 | $170.00K derived: sum of 2 quarters · filed 2026-05-01 | $255.00K derived: sum of 3 quarters · filed 2026-05-01 | $340.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $170.00K derived: sum of 2 quarters · filed 2026-02-27 | $255.00K derived: sum of 3 quarters · filed 2026-07-30 | $386.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $85.00K 10-Q · filed 2025-11-07 | $170.00K derived: sum of 2 quarters · filed 2026-07-30 | $301.00K 10-Q · filed 2025-11-07 | $434.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $85.00K 10-Q · filed 2026-07-30 | $217.00K 10-Q · filed 2026-07-30 | $349.00K derived: sum of 3 quarters · filed 2026-07-30 | $483.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $132.00K 10-Q · filed 2026-05-01 | $264.00K derived: sum of 2 quarters · filed 2026-05-01 | $398.00K derived: sum of 3 quarters · filed 2026-05-01 | $534.00K derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $266.00K derived: sum of 2 quarters · filed 2026-02-27 | $402.00K derived: sum of 3 quarters · filed 2026-02-27 | $539.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $134.00K 10-Q · filed 2025-11-07 | $270.00K derived: sum of 2 quarters · filed 2025-11-07 | $407.00K 10-Q · filed 2025-11-07 | $543.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $136.00K 10-Q · filed 2025-08-01 | $273.00K 10-Q · filed 2025-08-01 | $409.00K derived: sum of 3 quarters · filed 2026-02-27 | $545.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $137.00K 10-Q · filed 2025-05-02 | $273.00K derived: sum of 2 quarters · filed 2026-02-27 | $409.00K derived: sum of 3 quarters · filed 2026-02-27 | $652.00K derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $272.00K derived: sum of 2 quarters · filed 2026-02-27 | $515.00K derived: sum of 3 quarters · filed 2026-02-27 | $758.00K 10-K · filed 2026-02-27 |
| 2023-09-30 | $136.00K 10-Q · filed 2024-11-08 | $379.00K derived: sum of 2 quarters · filed 2024-11-08 | $622.00K 10-Q · filed 2024-11-08 | $815.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $243.00K 10-Q · filed 2024-08-02 | $486.00K 10-Q · filed 2024-08-02 | $679.00K derived: sum of 3 quarters · filed 2025-02-28 | $904.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $243.00K 10-Q · filed 2024-05-03 | $436.00K derived: sum of 2 quarters · filed 2025-02-28 | $661.00K derived: sum of 3 quarters · filed 2025-02-28 | $830.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $418.00K derived: sum of 2 quarters · filed 2025-02-28 | $587.00K derived: sum of 3 quarters · filed 2025-02-28 | $683.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | $225.00K 10-Q · filed 2023-11-03 | $394.00K derived: sum of 2 quarters · filed 2023-11-03 | $490.00K 10-Q · filed 2023-11-03 | $494.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $169.00K 10-Q · filed 2023-08-04 | $265.00K 10-Q · filed 2023-08-04 | $269.00K derived: sum of 3 quarters · filed 2024-02-28 | $272.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $96.00K 10-Q · filed 2023-05-05 | $100.00K derived: sum of 2 quarters · filed 2024-02-28 | $103.00K derived: sum of 3 quarters · filed 2024-02-28 | |
| 2021-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $7.00K derived: sum of 2 quarters · filed 2024-02-28 | $7.00K 10-K · filed 2024-02-28 | |
| 2021-09-30 | $3.00K 10-Q · filed 2022-11-07 | $3.00K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |